Parameter | Hazard Ratio | Lower 95% | Upper 95% | P value |
---|---|---|---|---|
Primary Cohort | ||||
ALC < 600 vs. ≥600 | 3.65 | 1.05 | 12.98 | 0.04 |
L% < 9 vs. ≥9 | 9.68 | 2.91 | 37.62 | 0.0002 |
NLR ≥7 vs. < 7 | 14.74 | 4.14 | 63.96 | < 0.0001 |
Expanded Cohort | ||||
ALC < 600 vs. ≥600 | 4.89 | 1.90 | 12.90 | 0.001 |
L% < 9 vs. ≥9 | 5.55 | 2.13 | 15.72 | 0.0004 |
NLR ≥7 vs. < 7 | 4.69 | 1.99 | 11.72 | 0.0004 |
Multivariate analyses were adjusted for the following independent variables: age, gender, race, smoking history, primary site of cancer, viral association, ECOG performance status, number of prior lines of therapy, and immunotherapy regimen; ALC Absolute lymphocyte count, L% Lymphocyte %, NLR Neutrophil-lymphocyte ratio